Skip to main content
SpringerLink
Log in

A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tilden DP, Mariz S, O’Bryan-Tear G, et al. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2007; 25 (1): 39–54

    Article  PubMed  Google Scholar 

  2. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects,of pioslitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547–1554

    Article  PubMed  CAS  Google Scholar 

  3. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice (JSB2). Heart 2005; 91 (Suppl. 5): vl–52

    Google Scholar 

  4. Charbonnel B, Dormandy J, Erdmann E, et al. Prospective pioglitazone clinical trial in macrovascular events (slide 73) [online]. Available from URL: http:/Avww.proactive-results.com/englishppt/frame.htm [Accessed 2007 Apr 16]

  5. Hanefeld M, Marx N, Pfutzner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity creactive protein: the PIOSTAT study. J Am Coll Cardiol 2007; 49 (3): 290–297

    Article  PubMed  CAS  Google Scholar 

  6. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Dec Mak 2002; 22 (4): 340–349

    Google Scholar 

  7. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005; 14: 217–30

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Philip Home has received funding on behalf of the University of Newcastle Upon Tyne, WorldWIDE (Worldwide Initiative for Diabetes Education) and the IDF (International Diabetes Federation) from the manufacturers of thiazolidinediones for research, development projects, consultation and teaching activities. Adrian Bagust and Matthew Taylor have received funding on behalf of the University of Liverpool Management School and the University of York, respectively, from GlaxoSmithKline for the development and application of a model investigating the cost effectiveness of rosiglitazone. Phil Ambery and Samara Mendes da Costa are employees of GlaxoSmithKline and are eligible to receive stock options in GSK.

Author information

Authors and Affiliations

  1. Department of Diabetes and Metabolism, University of Newcastle Upon Tyne, Newcastle, UK

    Philip Home

  2. University of Liverpool Management School, Liverpool, UK

    Adrian Bagust

  3. York Health Economics Consortium, University of York, York, UK

    Matthew Taylor

  4. GlaxoSmithKline, Uxbridge, UK

    Philip Ambery & Samara Mendes da Costa

Authors
  1. Philip Home
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrian Bagust
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philip Ambery
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samara Mendes da Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Home, P., Bagust, A., Taylor, M. et al. A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK. Pharmacoeconomics 25, 801–802 (2007). https://doi.org/10.2165/00019053-200725090-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200725090-00008

Keywords

Search

Navigation